MoBot’s Morning
DENVER, Colo., Apr 05, 2024 (247marketnews.com)- MoBot, the 24/7MN Momentum Bot, spotted the following listings- Mediaco (NASDAQ:MDIA), GCT Semiconductor Holding Inc. (NYSE:GCTS), and Candel Therapeutics, Inc. (NASDAQ:CADL).
Mediaco (NASDAQ:MDIA) announced that Chris Squire was named the Senior Vice President of Sales and Marketing for HOT 97 and WBLS, on January 2, 2024, and despite that being MDIA’s only news for the year, MoBot reminded everyone to keep an eye on it in this morning’s premarket, which it’s been doing consistently, since first mentioning it when it was trading at $1.082 on Monday.
MoBot liked GCT Semiconductor’s (NYSE:GCTS) Aramco news and spotted the move in the premarket, when it was at $7.241. GCTS reported signing a Memorandum of Understanding to form a strategic collaboration to design and co-develop chipsets and modules tailored for LTE, 5G and the NTN spectrum in order to support the localization of wireless end-user devices and IoT manufacturing throughout Saudi Arabia, including the development of the 4G/5G ecosystem throughout the Kingdom, for both mission-critical and public safety networks.
Candel Therapeutics (NASDAQ:CADL) was MoBot’s big winner, yesterday, after reporting updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409, spotted the move at $2.44 and CADL crossed $11 this morning.
Click here to view Mobot’s real time data.
To sign up for alerts, please click here.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (MDIA, GCTS, CADL)
- Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
- 24/7 Market News Snapshot 09 July, 2025 – Candel Therapeutics, Inc. Common Stock (NASDAQ:CADL)
- MoBot alert highlights: NYSE: WOLF, NASDAQ: VVPR, NASDAQ: CREV, NASDAQ: BMGL, NASDAQ: MDIA (07/07/25 01:00 PM)
- Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock